Utilization of kinase inhibitors as novel therapeutic drug targets: A review

被引:12
作者
Nishal, Suchitra [1 ]
Jhawat, Vikas [1 ]
Gupta, Sumeet [2 ]
Phaugat, Parmita [1 ]
机构
[1] GD Goenka Univ, Sch Med & Allied Sci, Dept Pharm, Gurugram, India
[2] Maharishi Markandeshwar Deemed Univ, Dept Pharmaceut Sci, Ambala, Haryana, India
关键词
Kinase inhibitors; Targeted; Drug designing; Anti-cancer; Auto-immune diseases; PLECKSTRIN HOMOLOGY DOMAIN; POTENT INHIBITOR; PROTEIN-KINASES; BLOOD-PRESSURE; ABL KINASE; IN-VITRO; BCR-ABL; MOLECULE; CANCER; DISCOVERY;
D O I
10.32604/or.2022.027549
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Kinase inhibitors are a significant and continuously developing division of target therapeutics. The drug discovery and improvement efforts have examined numerous attempts to target the signaling pathway of kinases. The Kinase inhibitors have been heralded as a game-changer in cancer treatment. For developing kinase inhibitors as a treatment for various non-malignant disorders like auto-immune diseases, is currently undergoing extensive research. It may be beneficial to investigate whether cell-specific kinase inhibitor administration enhances therapeutic efficacy and decreases adverse effects. The goal of the current review is to gain insight into the role of kinase inhibitors in facilitating effective target drug delivery for the treatment of various anti-inflammatory, auto-immune, and anticancer disorders. The aim of this review is also to shed light on drug discovery approaches for kinase inhibitors, their mode of action, and delivery approaches. The variation in the binding of kinases bestows different target approaches in drug design, which can be employed for designing the targeted molecules. Several target sites have been studied, exceeding the design of drugs for various diseases like cancer, Alzheimer's, rheumatoid arthritis, etc. Diverse delivery approaches have also been studied for the targeted application of kinase inhibitors.
引用
收藏
页码:221 / 230
页数:10
相关论文
共 98 条
  • [1] Adhami VM, 2004, MOL CANCER THER, V3, P933
  • [2] Ahad A. M., 2013, TARGETING PLECKSTRIN, V19, P108
  • [3] Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
    Ashton, Susan
    Song, Young Ho
    Nolan, Jim
    Cadogan, Elaine
    Murray, Jim
    Odedra, Rajesh
    Foster, John
    Hall, Peter A.
    Low, Susan
    Taylor, Paula
    Ellston, Rebecca
    Polanska, Urszula M.
    Wilson, Joanne
    Howes, Colin
    Smith, Aaron
    Goodwin, Richard J. A.
    Swales, John G.
    Strittmatter, Nicole
    Takats, Zoltan
    Nilsson, Anna
    Andren, Per
    Trueman, Dawn
    Walker, Mike
    Reimer, Corinne L.
    Troiano, Greg
    Parsons, Donald
    De Witt, David
    Ashford, Marianne
    Hrkach, Jeff
    Zale, Stephen
    Jewsbury, Philip J.
    Barry, Simon T.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (325)
  • [4] The insulin like growth factor-1 receptor (IGF-1R) as a drug target:: novel approaches to cancer therapy
    Bähr, C
    Groner, B
    [J]. GROWTH HORMONE & IGF RESEARCH, 2004, 14 (04) : 287 - 295
  • [5] Compounds from Natural Sources as Protein Kinase Inhibitors
    Baier, Andrea
    Szyszka, Ryszard
    [J]. BIOMOLECULES, 2020, 10 (11) : 1 - 30
  • [6] PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2
    Balendran, A
    Casamayor, A
    Deak, M
    Paterson, A
    Gaffney, P
    Currie, R
    Downes, CP
    Alessi, DR
    [J]. CURRENT BIOLOGY, 1999, 9 (08) : 393 - 404
  • [7] Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets
    Banik, Kishore
    Ranaware, Abhishek Manoj
    Deshpande, Vishwas
    Nalawade, Savita Pravin
    Padmavathi, Ganesan
    Bordoloi, Devivasha
    Sailo, Bethsebie Lalduhsaki
    Shanmugam, Muthu K.
    Fan, Lu
    Arfuso, Frank
    Sethi, Gautam
    Kunnumakkar, Ajaikumar B.
    [J]. PHARMACOLOGICAL RESEARCH, 2019, 144 : 192 - 209
  • [8] Chk1 and Chk2 kinases in checkpoint control and cancer
    Bartek, J
    Lukas, J
    [J]. CANCER CELL, 2003, 3 (05) : 421 - 429
  • [9] Discovery of a Potential Allosteric Ligand Binding Site in CDK2
    Betzi, Stephane
    Alam, Riazul
    Martin, Mathew
    Lubbers, Donna J.
    Han, Huijong
    Jakkaraj, Sudhakar R.
    Georg, Gunda I.
    Schoenbrunn, Ernst
    [J]. ACS CHEMICAL BIOLOGY, 2011, 6 (05) : 492 - 501
  • [10] Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies
    Bikker, Jack A.
    Brooijmans, Natasja
    Wissner, Allan
    Mansour, Tarek S.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (06) : 1493 - 1509